Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2026-04-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物关于公司会计政策变更的公告
Regulatory Filings Classification · 85% confidence The document is an official disclosure titled “关于公司会计政策变更的公告,” detailing the change in accounting policies under new Ministry of Finance rules. It is not an earnings release, financial report, audit report, dividend notice, or other specific category. It is a regulatory announcement of policy changes, fitting the fallback category for miscellaneous regulatory filings.
2026-04-14 Chinese
益方生物关于召开2025年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2025 annual performance explanation meeting (业绩说明会) to be held on April 17, 2026. It includes information on the meeting time, location, participants, and how investors can participate and ask questions. The document states that the company will release its 2025 annual report on April 15, 2026, but this document itself is not the annual report or the earnings release. It is a notice about an upcoming investor presentation event focused on discussing the annual results. The document length is short (1436 characters) and it does not contain financial data or detailed results, only the announcement of the event. Therefore, it fits best as an Investor Presentation (IP) announcement rather than the report itself or an earnings release. The document is not a report publication announcement (RPA) because it does not announce the release of the report but the scheduling of a meeting to discuss it. Hence, the classification is Investor Presentation (IP) with high confidence.
2026-04-09 Chinese
君合律师事务所上海分所关于益方生物科技（上海）股份有限公司终止实施2025年限制性股票激励计划的法律意见书
Regulatory Filings Classification · 60% confidence The document is a legal opinion letter from a law firm regarding the termination of the company’s 2025 restricted stock incentive plan. It does not present financial statements or discuss operational metrics, nor is it an earnings release, annual report, or other standard financial filing. It is a compliance/legal advisory document attached to the company’s disclosure but does not fit into any specialized category (e.g., M&A, audit report, remuneration proxy, dividend, share issue). Therefore, the appropriate classification is the generic Regulatory Filings category (RNS).
2026-03-27 Chinese
益方生物关于终止实施2025年限制性股票激励计划的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of 益方生物科技（上海）股份有限公司 regarding the termination of the 2025 restricted stock incentive plan. It details the decision-making process, reasons for termination, impact on the company, and legal opinions. The document is a formal announcement about a corporate governance and compensation-related decision, specifically about ending a stock incentive plan. It does not contain financial statements, audit information, or detailed financial data. It is not a full report like an Annual Report or Interim Report, nor is it a proxy solicitation or remuneration report. It is a regulatory announcement about a management decision related to stock incentives. Therefore, the best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2026-03-27 Chinese
益方生物第二届董事会2026年第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the company's board of directors meeting, specifically the termination of a 2025 restricted stock incentive plan. It details the meeting date, attendance, and voting results. There is no financial data or report content, only a formal announcement of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board. The document length is short and it is not a report or presentation, so it is not an Annual Report or Management Report. Therefore, the classification is MANG with high confidence.
2026-03-27 Chinese
益方生物自愿披露关于D-2570治疗银屑病注册性III期临床试验完成全部受试者入组的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a company about the completion of patient enrollment in a Phase III clinical trial for a drug (D-2570) targeting psoriasis. It provides detailed information about the drug, the clinical trial design, ongoing trials, and a risk warning. There are no financial statements, regulatory certifications, or voting results. The document is an announcement of a clinical trial milestone, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is Regulatory Filings (RNS) as a general announcement about clinical trial progress and company updates that do not fit other specific categories.
2026-03-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.